The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson’s disease

Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies

(2012) Jan-Peer Elshoff et al.   CLINICAL THERAPEUTICS

Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: A prospective, open-label extension study

(2012) Lawrence W. Elmer et al.   PARKINSONISM & RELATED DISORDERS

Current approaches to the treatment of Parkinson’s disease

(2011) Joseph Jankovic   Neuropsychiatric Disease and Treatment

Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease

(2010) Nir Giladi et al.   JOURNAL OF NEURAL TRANSMISSION

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER)

(2010) Claudia Trenkwalder et al.   MOVEMENT DISORDERS

Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease

(2009)   ARCHIVES OF NEUROLOGY

The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease

(2008) Dieter Scheller et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Current status of symptomatic medical therapy in Parkinson’s disease

(2008) Stewart A. Factor   Neurotherapeutics